S&P 500   3,009.87 (+0.10%)
DOW   26,813.82 (-0.05%)
QQQ   193.73 (+0.18%)
AAPL   241.03 (+0.22%)
FB   189.68 (-0.04%)
MSFT   139.21 (+0.56%)
AMZN   1,773.66 (-0.67%)
CGC   20.34 (-0.05%)
BABA   172.96 (-0.32%)
GE   8.63 (-1.82%)
TSLA   254.20 (+0.27%)
AMD   32.04 (+0.03%)
F   9.02 (-0.11%)
ACB   3.64 (-1.36%)
PRI   124.88 (-0.64%)
NFLX   269.83 (-2.96%)
GILD   66.10 (+1.36%)
DIS   132.45 (+1.68%)
S&P 500   3,009.87 (+0.10%)
DOW   26,813.82 (-0.05%)
QQQ   193.73 (+0.18%)
AAPL   241.03 (+0.22%)
FB   189.68 (-0.04%)
MSFT   139.21 (+0.56%)
AMZN   1,773.66 (-0.67%)
CGC   20.34 (-0.05%)
BABA   172.96 (-0.32%)
GE   8.63 (-1.82%)
TSLA   254.20 (+0.27%)
AMD   32.04 (+0.03%)
F   9.02 (-0.11%)
ACB   3.64 (-1.36%)
PRI   124.88 (-0.64%)
NFLX   269.83 (-2.96%)
GILD   66.10 (+1.36%)
DIS   132.45 (+1.68%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Heron TherapeuticsMadrigal PharmaceuticalsSupernus PharmaceuticalsCorcept TherapeuticsInsmed
SymbolNASDAQ:HRTXNASDAQ:MDGLNASDAQ:SUPNNASDAQ:CORTNASDAQ:INSM
Price Information
Current Price$19.28$87.99$26.55$13.97$18.49
52 Week RangeBuyBuyBuyBuyBuy
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$50.57$177.00$54.71$15.75$38.00
% Upside from Price Target162.30% upside101.16% upside106.08% upside12.74% upside105.52% upside
Trade Information
Market Cap$1.47 billion$1.33 billion$1.40 billion$1.56 billion$1.55 billion
Beta1.421.091.611.392.97
Average Volume1,305,070147,405505,418656,9771,027,112
Sales & Book Value
Annual Revenue$77.47 millionN/A$408.90 million$251.25 million$9.84 million
Price / Sales19.86N/A3.416.32167.63
CashflowN/AN/A$2.54 per share$0.67 per shareN/A
Price / CashN/AN/A10.4620.92N/A
Book Value$4.74 per share$30.99 per share$8.67 per share$2.39 per share$2.70 per share
Price / Book4.07N/A3.065.856.85
Profitability
Net Income$-178,840,000.00$-32,810,000.00$110.99 million$75.41 million$-324,280,000.00
EPS($2.44)($2.22)$2.05$0.60($4.17)
Trailing P/E RatioN/AN/A12.9523.28N/A
Forward P/E RatioN/AN/A13.9714.71N/A
P/E GrowthN/AN/A$0.90N/AN/A
Net Margins-172.07%N/A25.66%29.16%N/A
Return on Equity (ROE)-56.89%-11.62%22.36%27.97%-126.95%
Return on Assets (ROA)-45.19%-11.38%10.52%24.84%-47.66%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.04%N/A0.70%N/A1.01%
Current Ratio4.01%38.06%2.72%7.66%7.54%
Quick Ratio3.70%38.06%2.53%7.49%7.31%
Ownership Information
Institutional Ownership PercentageN/A61.79%99.14%75.16%N/A
Insider Ownership Percentage12.56%47.69%6.57%15.50%4.95%
Miscellaneous
Employees19817448166373
Shares Outstanding79.82 million15.43 million52.45 million113.69 million89.21 million
Next Earnings Date11/6/2019 (Estimated)11/5/2019 (Estimated)11/5/2019 (Estimated)11/7/2019 (Estimated)10/29/2019 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
 Heron TherapeuticsMadrigal PharmaceuticalsSupernus PharmaceuticalsCorcept TherapeuticsInsmed

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel